Table 1.
Baseline Characteristics
| BIS | BISVITD | P value | |
| N | 290 | 159 | - |
| Age (years) (SD*) | 75.1 (5.7) | 73.6 (5.6) | 0.011 |
| Women | 263 | 149 | 0.267 |
| Body mass index (kg/m2) (SD*) | 26.3 (4.9) | 25.3(3.7) | 0.024 |
| Bisphosphonate | |||
| - Etidronate | 89.3% | 95.0% | 0.042 |
| - Alendronate | 10.7% | 5.0% | |
| Years of bisphosphonates (SD*) | 5.9 (2.4) | 1 (0.0) | 0.001 |
| Calcium (mg/day) | |||
| - supplement | 658.2 | 757.1 | 0.002 |
| - dietary | 635.3 | 609.9 | 0.586 |
| - total | 1266.0 | 1319.0 | 0.369 |
| Previous exposure to | |||
| - estrogen | 37.6% | 30.4% | 0.127 |
| - fluoride | 9.0% | 8.8% | 0.955 |
| - calcitonin | 1.7% | 3.0% | 0.330 |
| Previous fracture | 68% | 69% | 0.786 |
| Weekly alcohol intake (ounces) | 1.63 | 1.26 | 0.537 |
| Smoking history | 32% | 35% | 0.616 |
| Corticosteroids | |||
| - systemic | 19.7% | 17.0% | 0.488 |
| - inhaled | 12.4% | 14.5% | 0.539 |
| Ever treated with | |||
| - non-steroidal anti-inflammatory | 39.7% | 35.2% | 0.356 |
| - thyroxin | 12.6% | 15.7% | 0.393 |
| β-blocker | 6.6% | 8.2% | 0.523 |
| - sedative-hypnotic | 7.2% | 6.3% | 0.704 |
| - thiazide | 7.2% | 6.3% | 0.704 |
| - calcium-channel blocker | 1.0% | 2.5% | 0.227 |
| - lipid-lowering agent | 0.3% | 2.5% | 0.036 |
| - anticonvulsants | 0.7% | 1.3% | 0.541 |
| - tamoxifen | 0.7% | 1.3% | 0.295 |
| - immunosuppressant | 0.0% | 1.9% | 0.019 |
| - chemotherapy | 0.0% | 0.0% | - |
| Laboratory values | |||
| - 25(OH)D (ng/mL) | 32.9 | 31.3 | 0.493 |
| - ALP(IU/L) | 90.7 | 94.0 | 0.474 |
| - Calcium (mmol/L) | 2.36 | 2.36 | 0.903 |
| - Phosphorus (mmol/L) | 1.13 | 1.14 | 0.539 |
| Baseline BMD (g/cm2) | |||
| - lumbar spine | 0.9287 | 0.8991 | 0.045 |
| - femoral neck | 0.7031 | 0.6850 | 0.081 |
*Standard Deviation